Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Purple Biotech presented preclinical data for its lead asset IM1240 at the EACR 2026 Congress, highlighting a broad therapeutic window and favorable safety profile. Non-human primate toxicology studies showed IM1240 has an 8-fold longer half-life and 16-fold greater exposure than the non-capped variant, with a >300-fold improvement in the dose required to trigger cytokine release.
Key figures
- Drug Name
- IM1240
- Exposure improvement
- 16-fold greater vs non-capped variant
- Clearance improvement
- ~14-fold slower clearance vs non-capped variant
- Half life improvement
- 8-fold longer vs non-capped variant
- Cytokine safety margin
- >300-fold difference in dose required to trigger cytokine release vs non-capped variant
- First in human timeline
- 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.